HPV DNA, E6 iI-mRNA expression and p16 INK4A immunohistochemistry in head and neck cancer - How valid is p16 INK4A as surrogate marker?

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 88-96

  Hoffmann, Markus ^a   Tribius, Silke ^b   Quabius, Elgar Susanne ^a   Henry, Hannes ^a   Pfannenschmidt, Saskia ^a   Burkhardt, Claudia ^a   Görögh, Tibor ^a   Halec, Gordana ^c   Hoffmann, Anna Sophie ^d   Kahn, Tomas ^e   Röcken, Christoph ^a   Haag, Jochen ^a   Waterboer, Tim ^c   Schmitt, Markus ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e DEUTSCHE BANK AG   (Germany)

Author keywords

BSGP5+ 6+ PCR MPG; E6mRNA; Head and neck cancer; HNSCC; HPV; Human papillomavirus; Multiplex HPV genotyping; P16; Viral load

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; VIRUS DNA;

ACCURACY; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DNA DETERMINATION; E6 I GENE; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREDICTION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; TONSIL CARCINOMA; TUMOR LOCALIZATION; VIRUS GENE; VIRUS LOAD;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; TONSILLAR NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84861837913     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.033     Document Type: Article

References (57)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24:2137-2150.
2. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011, 11:9-22.
3. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
4. Smith E.M., Rubenstein L.M., Haugen T.H., Hamsikova E., Turek L.P. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control 2010, 21:1369-1378.
5. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005, 14:467-475.
6. Termine N., Panzarella V., Falaschini S., Russo A., Matranga D., Lo M.L., Campisi G. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann. Oncol. 2008, 19:1681-1690.
7. zur H.H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009, 384:260-265.
8. de Villiers E.M., Weidauer H., Otto H., zur H.H. Papillomavirus DNA in human tongue carcinomas. Int. J. Cancer 1985, 36:575-578.
9. Kahn T., Schwarz E., zur H.H. Molecular cloning and characterization of the DNA of a new human papillomavirus (HPV 30) from a laryngeal carcinoma. Int. J. Cancer 1986, 37:61-65.
10. Syrjanen K., Syrjanen S., Pyrhonen S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. ORL J. Otorhinolaryngol. Relat. Spec. 1982, 44:323-334.
11. Ang K.K., Harris J., Wheeler R., Weber R., Rosenthal D.I., Nguyen-Tan P.F., Westra W.H., Chung C.H., Jordan R.C., Lu C., Kim H., Axelrod R., Silverman C.C., Redmond K.P., Gillison M.L. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl. J. Med. 2010, 363:24-35.
12. Gillison M.L. HPV and prognosis for patients with oropharynx cancer. Eur. J. Cancer 2009, 45(Suppl. 1):383-385.
13. Smith E.M., Ritchie J.M., Summersgill K.F., Klussmann J.P., Lee J.H., Wang D., Haugen T.H., Turek L.P. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int. J. Cancer 2004, 108:766-772.
14. Smith E.M., Pawlita M., Rubenstein L.M., Haugen T.H., Hamsikova E., Turek L.P. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int. J. Cancer 2010, 127:111-117.
15. Tribius S., Ihloff A.S., Rieckmann T., Petersen C., Hoffmann M. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett. 2011, 304:71-79.
16. Hoffmann M., Kahn T., Mahnke C.G., Goeroegh T., Lippert B.M., Werner J.A. Prevalence of human papillomavirus in squamous cell carcinoma of the head and neck determined by polymerase chain reaction and Southern blot hybridization: proposal for optimized diagnostic requirements. Acta Otolaryngol. 1998, 118:138-144.
17. Hoffmann M., Ihloff A.S., Gorogh T., Weise J.B., Fazel A., Krams M., Rittgen W., Schwarz E., Kahn T. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int. J. Cancer 2010, 127:1595-1602.
18. Blomberg M., Nielsen A., Munk C., Kjaer S.K. Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int. J. Cancer 2010, 129:733-741.
19. Marklund L., Hammarstedt L. Impact of HPV in oropharyngeal cancer. J. Oncol. 2011, 2011:509036.
20. Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., Ahrlund-Richter S., Marklund L., Romanitan M., Lindquist D., Ramqvist T., Lindholm J., Sparen P., Ye W., Dahlstrand H., Munck-Wikland E., Dalianis T. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int. J. Cancer 2009, 125:362-366.
21. Ribeiro K.B., Levi J.E., Pawlita M., Koifman S., Matos E., Eluf-Neto J., Wunsch-Filho V., Curado M.P., Shangina O., Zaridze D., Szeszenia-Dabrowska N., Lissowska J., Daudt A., Menezes A., Bencko V., Mates D., Fernandez L., Fabianova E., Gheit T., Tommasino M., Boffetta P., Brennan P., Waterboer T. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int. J. Epidemiol 2011, 40:489-502.
22. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001, 20:7874-7887.
23. Munger K., Basile J.R., Duensing S., Eichten A., Gonzalez S.L., Grace M., Zacny V.L. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001, 20:7888-7898.
24. Munger K., Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 2002, 89:213-228.
25. Malanchi I., Caldeira S., Krutzfeldt M., Giarre M., Alunni-Fabbroni M., Tommasino M. Identification of a novel activity of human papillomavirus type 16 E6 protein in deregulating the G1/S transition. Oncogene 2002, 21:5665-5672.
26. zur H.H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.
27. Jones D.L., Alani R.M., Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 1997, 11:2101-2111.
28. Andl T., Kahn T., Pfuhl A., Nicola T., Erber R., Conradt C., Klein W., Helbig M., Dietz A., Weidauer H., Bosch F.X. Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res. 1998, 58:5-13.
29. Wiest T., Schwarz E., Enders C., Flechtenmacher C., Bosch F.X. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002, 21:1510-1517.
30. Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., Dallenbach-Hellweg G., Schmidt D., von Knebel D.M. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 2001, 92:276-284.
31. Nguyen C.L., Munger K. Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J. Virol. 2009, 83:1700-1707.
32. Shin M.K., Balsitis S., Brake T., Lambert P.F. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 2009, 69:5656-5663.
33. McLaughlin-Drubin M.E., Crum C.P., Munger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. USA 2011, 108:2130-2135.
34. Smeets S.J., Hesselink A.T., Speel E.J., Haesevoets A., Snijders P.J., Pawlita M., Meijer C.J., Braakhuis B.J., Leemans C.R., Brakenhoff R.H. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int. J. Cancer 2007, 121:2465-2472.
35. O'Regan E.M., Toner M.E., Finn S.P., Fan C.Y., Ring M., Hagmar B., Timon C., Smyth P., Cahill S., Flavin R., Sheils O.M., O'Leary J.J. p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum. Pathol. 2008, 39:452-458.
36. Smeets S.J., van der Plas M., Schaaij-Visser T.B., van Veen E.A., van M.J., Braakhuis B.J., Steenbergen R.D., Brakenhoff R.H. Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int. J. Cancer 2011, 128:1596-1605.
37. Jung A.C., Briolat J., Millon R., de R.A., Rickman D., Thomas E., Abecassis J., Clavel C., Wasylyk B. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int. J. Cancer 2010, 126:1882-1894.
38. Saiki R.K., Scharf S., Faloona F., Mullis K.B., Horn G.T., Erlich H.A., Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985, 230:1350-1354.
39. van Dongen J.J., Langerak A.W., Bruggemann M., Evans P.A., Hummel M., Lavender F.L., Delabesse E., Davi F., Schuuring E., Garcia-Sanz R., van Krieken J.H., Droese J., Gonzalez D., Bastard C., White H.E., Spaargaren M., Gonzalez M., Parreira A., Smith J.L., Morgan G.J., Kneba M., Macintyre E.A. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
40. Schmitt M., Bravo I.G., Snijders P.J., Gissmann L., Pawlita M., Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 2006, 44:504-512.
41. Schmitt M., Dondog B., Waterboer T., Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J. Clin. Microbiol. 2008, 46:1050-1059.
42. Schmitt M., Dondog B., Waterboer T., Pawlita M., Tommasino M., Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J. Clin. Microbiol. 2010, 48:143-149.
43. D.Holzinger, M. Schmitt, G. Dyckhoff, A. Benner, M. Pawlita, F.X. Bosch. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Research, Submitted for publication.
44. Remmerbach T.W., Brinckmann U.G., Hemprich A., Chekol M., Kuhndel K., Liebert U.G. PCR detection of human papillomavirus of the mucosa: comparison between MY09/11 and GP5+/6+ primer sets. J. Clin. Virol. 2004, 30:302-308.
45. Halec G., Schmitt M., Dondog B., Sharkhuu E., Wentzensen N., Gheit T., Tommasino M., Kommoss F., Bosch F.X., Franceschi S., Clifford G., Gissmann L., Pawlita M. Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int. J. Cancer 2012.
46. Agger K., Cloos P.A., Rudkjaer L., Williams K., Andersen G., Christensen J., Helin K. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009, 23:1171-1176.
47. Barradas M., Anderton E., Acosta J.C., Li S., Banito A., Rodriguez-Niedenfuhr M., Maertens G., Banck M., Zhou M.M., Walsh M.J., Peters G., Gil J. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 2009, 23:1177-1182.
48. Bueno M.J., Malumbres M. MicroRNAs and the cell cycle. Biochim. Biophys. Acta 2011, 1812:592-601.
49. Yamakoshi K., Takahashi A., Hirota F., Nakayama R., Ishimaru N., Kubo Y., Mann D.J., Ohmura M., Hirao A., Saya H., Arase S., Hayashi Y., Nakao K., Matsumoto M., Ohtani N., Hara E. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J. Cell Biol. 2009, 186:393-407.
50. Hoffmann M., Gorogh T., Gottschlich S., Lohrey C., Rittgen W., Ambrosch P., Schwarz E., Kahn T. Human papillomaviruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett. 2005, 218:199-206.
51. Rischin D., Young R.J., Fisher R., Fox S.B., Le Q.T., Peters L.J., Solomon B., Choi J., O'Sullivan B., Kenny L.M., McArthur G.A. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J. Clin. Oncol. 2010, 28:4142-4148.
52. Klingenberg B., Hafkamp H.C., Haesevoets A., Manni J.J., Slootweg P.J., Weissenborn S.J., Klussmann J.P., Speel E.J. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology 2010, 56:957-967.
53. Klussmann J.P., Gultekin E., Weissenborn S.J., Wieland U., Dries V., Dienes H.P., Eckel H.E., Pfister H.J., Fuchs P.G. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am. J. Pathol. 2003, 162:747-753.
54. Schmitt M., Dalstein V., Waterboer T., Clavel C., Gissmann L., Pawlita M. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res. 2010, 70:249-256.
55. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., Forastiere A., Gillison M.L. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 2008, 100:261-269.
56. Baumann J.L., Cohen S., Evjen A.N., Law J.H., Vadivelu S., Attia A., Schindler J.S., Chung C.H., Wirth P.S., Meijer C.J., Snijders P.J., Yarbrough W.G., Slebos R.J. Human papillomavirus in early laryngeal carcinoma. Laryngoscope 2009, 119:1531-1537.
57. Petersen I., Schewe C., Schluns K., Dietel M., Speich N., Schmitt C., Bollmann M., Sotlar K., Bultmann B., Dours-Zimmermann M.T., Padberg B., Zimmermann D.R. Inter-laboratory validation of PCR-based HPV detection in pathology specimens. Virchows Arch. 2007, 451:701-716.